bluebird bio Inc
NASDAQ:BLUE
NASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)

  • LAST PRICE
    0.9522
  • TODAY'S CHANGE (%)
    -0.0074 (-0.7712%)
  • Bid / Lots
    0.9500/ 51
  • Ask / Lots
    0.9700/ 100
  • Open / Previous Close
    0.9510 / 0.9596
  • Day Range
    0.9374
    1.0100
  • 52 Week Range
    0.8510
    5.5300
  • Volume
    7,132,011

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BLUE
bluebird bio Inc
182.7M
-1.3x
---
ABEO
Abeona Therapeutics Inc
188.2M
-1.4x
---
GBIO
Generation Bio Co
182.3M
-1.1x
---
ADVM
Adverum Biotechnologies Inc
158.2M
-0.7x
---
OTLK
Outlook Therapeutics Inc
179.5M
-0.7x
---
XBIT
XBiotech Inc
185.8M
-6.0x
---
As of 2024-06-17

Company Information

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).

Contact Information

Headquarters
455 Grand Union BoulevardSOMERVILLE, MA, United States 02145
Phone
339-499-9300
Fax
302-636-5454

Executives

Independent Chairman of the Board
Mark Vachon
President, Chief Executive Officer, Director
Andrew Obenshain
Chief Financial Officer
O. James Sterling
Chief Commercial and Operating Officer
Thomas Klima
Chief Medical Officer
Richard Colvin

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$182.7M
Revenue (TTM)
$21.7M
Shares Outstanding
190.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.82
EPS
$-0.74
Book Value
$2.37
P/E Ratio
-1.3x
Price/Sales (TTM)
8.4
Price/Cash Flow (TTM)
---
Operating Margin
-626.69%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.